Senior Biostatistician

A Senior Biostatistician designs the statistical framework that determines whether a clinical trial can answer the question it was designed to ask, then executes the analysis that provides the answer. The quality of that work has direct consequences: a trial with an underpowered sample size fails to detect a real effect; a primary endpoint that doesn't measure what patients and physicians care about doesn't support approval even if the statistics are clean; an SAP that didn't pre-specify a key analysis creates regulatory ambiguity that delays or blocks the filing.

The design work happens early. Before a Phase III trial enrolls a single patient, the senior biostatistician has defined the primary endpoint, calculated the sample size based on expected effect size and variability, specified how multiplicity across secondary endpoints will be controlled, determined what the interim analysis strategy will be, and documented all of this in a SAP that the FDA can review as part of a Special Protocol Assessment. The care taken in that pre-specification is the foundation of regulatory credibility for the eventual analysis.

The analysis work happens after database lock. The biostatistician runs the pre-specified analysis programs on validated datasets, generates the tables, figures, and listings for the clinical study report, reviews the output for anomalies, and works with the clinical team to interpret results in a clinical context. When results are surprising — a drug that worked in a different population than expected, a safety signal that appeared in a subgroup — the biostatistician determines what pre-specified analyses can address those observations and what would constitute post-hoc data exploration.

The regulatory interface is a significant senior-level responsibility. FDA statisticians in CDER and CDRH are sophisticated counterparts who will replicate analyses on submitted data, probe the assumptions behind sample size calculations, and question multiplicity control strategies. Senior biostatisticians who understand how regulatory statisticians think — and who engage with them early through pre-submission meetings — move their programs through review more efficiently.

Education:

• MS in biostatistics, statistics, or a related quantitative field is the minimum standard for senior roles
• PhD strongly preferred by large pharmaceutical companies and for roles with significant regulatory responsibility
• BS candidates with extensive experience can sometimes reach mid-level biostatistician roles but rarely senior level without graduate work

Regulatory and clinical knowledge:

• ICH E8, E9, E9(R1) (clinical trial design, statistical principles, estimands)
• ICH E6 (GCP) and understanding of clinical trial operations
• FDA guidance on adaptive designs, master protocols, and real-world evidence
• NDA/BLA submission experience including ISS, ISE, and CTD Module 5 statistical sections

Technical and programming:

• SAS: Base, STAT, MACRO, GRAPH — regulatory submission-grade proficiency
• R: mixed-effects models, survival analysis, complex simulation, visualization (ggplot2)
• CDISC: SDTM and ADaM standards; experience validating ADaM dataset structure and specifications
• Pinnacle 21 or OpenCDISC validation tools

Statistical methodology:

• Survival analysis: Kaplan-Meier, Cox proportional hazards, competing risks
• Mixed models for repeated measures (MMRM): assumptions, implementation, interpretability
• Multiple comparison procedures: FWER control, Hochberg, Bonferroni, gate-keeping strategies
• Missing data methods: multiple imputation, tipping point analysis, sensitivity analysis frameworks
• Sample size and power calculation for complex endpoints and adaptive designs
• Bayesian methods: increasing relevance in adaptive and platform trial design

Soft skills:

• Scientific communication: explaining statistical reasoning to non-statistician team members and regulatory reviewers
• Project management: tracking multiple trials in parallel with overlapping analysis timelines
• Mentoring: developing junior biostatisticians through review, feedback, and study assignment

Biostatistics is among the most secure quantitative career paths in the life sciences. The pharmaceutical and biotech industries require biostatisticians for every clinical trial — not as a nice-to-have, but as a regulatory requirement. Every NDA and BLA submitted to FDA must include statistical analysis by qualified biostatisticians, and FDA reviewers expect to engage with the sponsor's statistical team during review. That regulatory necessity creates a floor of demand that doesn't disappear with pipeline cycles.

The growth of complex trial designs has increased the value of senior biostatisticians relative to more junior roles. Platform trials, basket and umbrella designs, Bayesian adaptive designs, and real-world evidence studies require sophisticated statistical architecture that junior biostatisticians can't provide independently. Companies running innovative development programs need senior statistical talent to design these studies credibly and to defend them to regulators.

CROs have been major employers of biostatisticians, and that segment has grown as pharmaceutical companies outsource more statistical work. Senior biostatisticians at CROs work across multiple therapeutic areas and see a broader range of trial designs than those at single-sponsor companies, which builds versatile expertise. Turnover is higher at CROs but so is the breadth of exposure.

Digital health and real-world evidence are generating new demand. Analyzing electronic health records, wearable device data, and registry data for regulatory purposes requires statistical expertise — including understanding of the specific biases and limitations of non-randomized data — that overlaps substantially with clinical trial biostatistics.

Career progression from Senior Biostatistician leads to Principal Biostatistician or Group Statistical Director, then to VP or Head of Statistics. VPs of Biometrics at major pharmaceutical companies earn $200K–$280K with bonus and equity. Many biostatisticians stay at the Principal or Executive level on the IC track, earning $155K–$185K, and find the work more intellectually satisfying than managing large biometrics organizations.

Dear Hiring Manager,

I'm applying for the Senior Biostatistician position at [Company]. I have eight years of pharmaceutical biostatistics experience, the last four at [Company], where I've been the lead statistician on two Phase III trials in [therapeutic area] including one pivotal study that was part of a recently filed NDA.

For the pivotal trial, I led the SAP development, designed the primary and key secondary analyses, and managed the interim analysis process through an independent DMC. The study used a hierarchical testing procedure to control family-wise error rate across the primary endpoint and four key secondary endpoints, and I worked with the clinical team for several months to align on the analysis hierarchy before the protocol was finalized. When FDA requested a pre-submission meeting on the statistical analysis plan, I was the primary statistical contact and addressed reviewers' questions on the missing data sensitivity analysis strategy directly.

On the programming side, I lead a small team of statistical programmers and validate the ADaM datasets and primary analysis programs myself before external validation. I've been the unblinded biostatistician for the DMC reporting function on two trials and understand the data governance requirements around interim analyses.

I'm interested in [Company] because of your [specific pipeline or methodological area of interest]. I'd welcome the opportunity to discuss the role and your team's current statistical priorities.

Thank you for your time.

[Your Name]